<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): May 15, 2009</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>IMMTECH PHARMACEUTICALS, INC.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>001-14907</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>39-1523370</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>One North End Avenue<BR>New York, New York<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>10282</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(212) 791-2911</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>&nbsp;</B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="left" style="font-size: 10pt"><B>ITEM 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.</B>


<P align="left" style="font-size: 10pt; text-indent: 7%">As previously announced, Immtech Pharmaceuticals, Inc. (the &#147;Company&#148;) was notified on March&nbsp;27, 2009 by the staff
of the Corporate Compliance Department of NYSE Regulation, Inc. (the &#147;Staff&#148;), on behalf of NYSE Amex LLC, f/k/a NYSE
Alternext US LLC (the &#147;Exchange&#148;), that the Company was not in compliance with certain of the Exchange&#146;s continued
listing standards, as set forth in the Exchange&#146;s Company Guide (the &#147;Company Guide&#148;), including Section&nbsp;1003(a)(ii),
Section&nbsp;1003(a)(iii) and Section&nbsp;1003(a)(iv). In response to such notification, the Company, in accordance with Part
12 of the Company Guide, requested a hearing before the Listing Qualifications Panel of the Exchange&#146;s Committee on
Securities (the &#147;Panel&#148;) to review the Staff&#146;s determination.


<P align="left" style="font-size: 10pt; text-indent: 7%">On May&nbsp;13, 2009, the Panel held a hearing to consider the written and oral submissions made by the Company and the
Staff. On May&nbsp;15, 2009, the Global Legal Department (the &#147;Department&#148;) of NYSE Euronext notified the Company that the
Panel unanimously affirmed the Staff&#146;s earlier determination to delist the common stock of the Company. In its letter,
the Panel agreed with, and the Company did not dispute, the Staff&#146;s analysis that the Company was not in compliance
with Section&nbsp;1003(a)(iii) of the Company Guide, with stockholders&#146; equity of less than $6&nbsp;million and losses sustained
from continuing operations and/or net losses in its five most recent fiscal years. The Company has determined not to
request a review of the Panel&#146;s decision by the Exchange&#146;s Committee on Securities and has confirmed with the Exchange
that trading in the Company&#146;s common stock on the Exchange will be suspended effective after the close of trading on
Thursday, May&nbsp;21, 2009.


<P align="left" style="font-size: 10pt; text-indent: 7%">On May&nbsp;21, 2009, the Company issued a press release (the &#147;Press Release&#148;) announcing that it had received the
Panel&#146;s determination and that it is in the process of facilitating the transition of the trading of its common stock
to the over-the-counter (&#147;OTC&#148;) market. The Company expects its common stock to begin quotation on the Pink OTC
Markets quotation system on or about Friday, May&nbsp;22, 2009. A copy of the Press Release is attached to this Current
Report on Form 8-K as Exhibit&nbsp;99.1 and is incorporated herein by reference.


<P align="left" style="font-size: 10pt"><B>ITEM 9.01 Financial Statements and Exhibits.</B>


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Exhibits</TD>
</TR>

</TABLE>


<P align="left" style="font-size: 10pt">The following exhibits are filed herewith:

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="11%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="84%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Exhibit</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release, dated as of May&nbsp;21, 2009.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt; text-indent: 7%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left"><B>IMMTECH PHARMACEUTICALS, INC.</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Date: May&nbsp;21, 2009
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>/s/ Eric L. Sorkin</U></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Eric L. Sorkin</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chairman, Chief Executive Officer and President</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">





<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">





<P align="center" style="font-size: 10pt"><U><B>EXHIBIT INDEX</B></U>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="11%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="84%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Exhibit</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release, dated as of May&nbsp;21, 2009.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">4




</DIV>
</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "c86008e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 11594}]
{"company-data": {"conformed-name": "IMMTECH PHARMACEUTICALS, INC.", "cik": "0000882509", "assigned-sic": "2836", "irs-number": "391523370", "state-of-incorporation": "DE", "fiscal-year-end": "0331"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14907", "film-number": "09846068"}, "business-address": {"street1": "150 FAIRWAY DRIVE", "street2": "SUITE 150", "city": "VERNON HILLS", "state": "IL", "zip": "60061", "phone": "(847) 573-0033"}, "mail-address": {"street1": "150 FAIRWAY DRIVE", "street2": "SUITE 150", "city": "VERNON HILLS", "state": "IL", "zip": "60061"}, "former-company": {"former-conformed-name": "IMMTECH INTERNATIONAL INC", "date-changed": "19980824"}}
Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 15, 2009
IMMTECH PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
001-14907
39-1523370
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
One North End Avenue
New York, New York
10282
(Address of Principal Executive Offices)
(Zip Code)
Registrant's telephone number, including area code:
(212) 791-2911
(Former name or former address if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
As previously announced, Immtech Pharmaceuticals, Inc. (the "Company") was notified on March 27, 2009 by the staff
of the Corporate Compliance Department of NYSE Regulation, Inc. (the "Staff"), on behalf of NYSE Amex LLC, f/k/a NYSE
Alternext US LLC (the "Exchange"), that the Company was not in compliance with certain of the Exchange's continued
listing standards, as set forth in the Exchange's Company Guide (the "Company Guide"), including Section 1003(a)(ii),
Section 1003(a)(iii) and Section 1003(a)(iv). In response to such notification, the Company, in accordance with Part
12 of the Company Guide, requested a hearing before the Listing Qualifications Panel of the Exchange's Committee on
Securities (the "Panel") to review the Staff's determination.
On May 13, 2009, the Panel held a hearing to consider the written and oral submissions made by the Company and the
Staff. On May 15, 2009, the Global Legal Department (the "Department") of NYSE Euronext notified the Company that the
Panel unanimously affirmed the Staff's earlier determination to delist the common stock of the Company. In its letter,
the Panel agreed with, and the Company did not dispute, the Staff's analysis that the Company was not in compliance
with Section 1003(a)(iii) of the Company Guide, with stockholders' equity of less than $6 million and losses sustained
from continuing operations and/or net losses in its five most recent fiscal years. The Company has determined not to
request a review of the Panel's decision by the Exchange's Committee on Securities and has confirmed with the Exchange
that trading in the Company's common stock on the Exchange will be suspended effective after the close of trading on
Thursday, May 21, 2009.
On May 21, 2009, the Company issued a press release (the "Press Release") announcing that it had received the
Panel's determination and that it is in the process of facilitating the transition of the trading of its common stock
to the over-the-counter ("OTC") market. The Company expects its common stock to begin quotation on the Pink OTC
Markets quotation system on or about Friday, May 22, 2009. A copy of the Press Release is attached to this Current
Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
ITEM 9.01 Financial Statements and Exhibits.
(d)
Exhibits
The following exhibits are filed herewith:
No.
Exhibit
99.1
Press release, dated as of May 21, 2009.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.
IMMTECH PHARMACEUTICALS, INC.
Date: May 21, 2009
/s/ Eric L. Sorkin
Eric L. Sorkin
Chairman, Chief Executive Officer and President
EXHIBIT INDEX
No.
Exhibit
99.1
Press release, dated as of May 21, 2009.